Exscientia Plc logo

Exscientia Plc Share Price (NASDAQ: EXAI)

▲

-4.84

(-100%)

Live

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 19 Nov 2024

Check the interactive Exscientia Plc Stock chart to analyse performance

Exscientia Plc Key Stats

Check Exscientia Plc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$4.84
Open
$4.63
Market Capitalization
$633.2M
Today's Volume
$1.5M
Revenue TTM
$17.1M
EBITDA
$-148.7M
Earnings Per Share (EPS)
$-1.51
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-46.43%

Global Institutional Holdings in Exscientia Plc

  • Name

    Holdings %

  • Novo A/S

    10.00%

  • SoftBank Group Corp

    4.34%

  • LAURION CAPITAL MANAGEMENT LP

    3.42%

  • Baillie Gifford & Co Limited.

    2.94%

  • First Trust Advisors L.P.

    1.32%

  • Bill & Melinda Gates Foundation

    1.22%

Analyst Recommendation on Exscientia Plc Stock

Rating
Trend

Buy

    66%Buy

    33%Hold

    0%Sell

Based on 9 Wall street analysts offering stock ratings for Exscientia Plc(by analysts ranked 0 to 5 stars)

About Exscientia Plc

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité " Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Organization
Exscientia Plc
Employees
483
CEO
Dr. David Hallett Ph.D.
Industry
Miscellaneous

Important FAQs about investing in EXAI Stock from India :

What is Exscientia Plc share price today?

Exscientia Plc share price today is as on . Exscientia Plc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Exscientia Plc share?

Exscientia Plc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Exscientia Plc stock price today i.e. is trending at , lower by 100% versus the 52 week high.

How to invest in Exscientia Plc Stock (EXAI) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Exscientia Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Exscientia Plc Shares .

What is the minimum amount required to buy Exscientia Plc Stock (EXAI) from India?

Indian investors can start investing in Exscientia Plc (EXAI) shares with as little as ₹88.425 or $1 (as of September 11, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹884.25 in Exscientia Plc stock (as per the Rupee-Dollar exchange rate as on September 11, 2025). Learn more about fractional shares .

What are the returns that Exscientia Plc has given to Indian investors in the last 5 years?

Exscientia Plc stock has given 0.0% share price returns and 20.4% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?